Heat Biologics Provides Third Quarter 2021 Business Update

NEXT STORY
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
PREV STORY
Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

author_avatar
NASDAQ Market News

Knight Announces Filing of New Drug Submission for Ibsrela™ in Canada

author_avatar
NASDAQ Market News

Global Immunoassay Market Will Reach USD 29.79 Billion By 2025: Zion Market Research

author_avatar
NASDAQ Market News